School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

MANNKIND CORP MNKD

Healthcare · Biotechnology

$3.29last close 2026-10-09 · market cap $1.06B · delayed data

Trailing returns

1M-16.50%
3M-20.53%
6M+28.52%
1Y-35.99%
5Y-35.74%

Basis: Adjusted daily closes.

What it does

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

Open MNKD in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies